GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (STU:2GH) » Definitions » Deferred Tax

Merus NV (STU:2GH) Deferred Tax : €1.97 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Merus NV Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Merus NV's change in deferred tax for the three months ended in Mar. 2024 was €0.85 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Mar. 2024 was €1.97 Mil.

Merus NV Deferred Tax Historical Data

The historical data trend for Merus NV's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus NV Deferred Tax Chart

Merus NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Deferred Tax
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.08 -0.10 -0.01 -1.53 0.77

Merus NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.31 -0.63 2.21 -0.46 0.85

Merus NV Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.97 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merus NV Deferred Tax Related Terms

Thank you for viewing the detailed overview of Merus NV's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Merus NV (STU:2GH) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (STU:2GH) » Definitions » Deferred Tax
Comparable Companies
ABCL CVAC RYZB HRMY AGIO ZNTL RXRX MNKD TGTX SAGE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
MRUS:USA 2GH:Germany
Address
Uppsalalaan 17, Utrecht, NLD, 3584 CT
Website
https://www.merus.nl
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Merus NV (STU:2GH) Headlines

No Headlines